Ingrid Gause‐Nilsson

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6K citations · Full text

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 656 citations · Full text

Metabolic Syndrome, Declare–timi 58, Diabetes Management +10

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 550 citations

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado et al. · Circulation · 2020 · 428 citations · Full text

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

Remo H.M. Furtado, Marc P. Bonaca, Itamar Raz et al. · Circulation · 2019 · 327 citations